Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Current Assets: 2017-2025

Historic Current Assets for Fennec Pharmaceuticals (FENC) over the last 7 years, with Sep 2025 value amounting to $46.1 million.

  • Fennec Pharmaceuticals' Current Assets fell 20.53% to $46.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.1 million, marking a year-over-year decrease of 20.53%. This contributed to the annual value of $44.1 million for FY2024, which is 64.29% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Current Assets is $46.1 million, which was up 12.92% from $40.8 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Current Assets registered a high of $68.2 million during Q1 2024, and its lowest value of $15.6 million during Q2 2022.
  • Moreover, its 3-year median value for Current Assets was $43.0 million (2025), whereas its average is $40.9 million.
  • Per our database at Business Quant, Fennec Pharmaceuticals' Current Assets tumbled by 44.60% in 2022 and then surged by 221.62% in 2024.
  • Quarterly analysis of 5 years shows Fennec Pharmaceuticals' Current Assets stood at $26.0 million in 2021, then increased by 16.07% to $26.7 million in 2022, then climbed by 0.49% to $26.9 million in 2023, then skyrocketed by 64.29% to $44.1 million in 2024, then decreased by 20.53% to $46.1 million in 2025.
  • Its last three reported values are $46.1 million in Q3 2025, $40.8 million for Q2 2025, and $43.0 million during Q1 2025.